<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623710</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN2050-HV-108</org_study_id>
    <nct_id>NCT04623710</nct_id>
  </id_info>
  <brief_title>Study of ALXN2050 in Participants With Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple-Dose, Parallel Study to Determine the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ALXN2050 in Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the impact of impaired renal function on the plasma&#xD;
      pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future&#xD;
      indications in individuals with impaired renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will initiate (Part 1) with participants with severe impaired renal function&#xD;
      (Cohort 1) and their matched healthy control participants (Cohort 4). Following data review,&#xD;
      the study may proceed (Part 2) with participants with moderate (Cohort 2) and mild (Cohort 3)&#xD;
      impaired renal function if deemed necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum (Peak) Steady-state Plasma Concentration (Cmax,ss) Of Plasma ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Complement Factor D Concentration At 24, 48, And 72 Hours Postdose</measure>
    <time_frame>Baseline, 24, 48, and 72 hours postdose</time_frame>
    <description>This information will be collected using a plasma enzyme-linked immunosorbent assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Plasma b Fragment Of Complement Factor B Concentration</measure>
    <time_frame>Baseline, up to 72 hours postdose</time_frame>
    <description>This information will be collected using a plasma enzyme-linked immunosorbent assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Complement Alternative Pathway Hemolysis Activity</measure>
    <time_frame>Baseline, up to 72 hours postdose</time_frame>
    <description>This information will be collected using a serum complement alternative pathway functional assay, rabbit erythrocytes, and colorimetric endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)]</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Severe Impaired Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2050.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Moderate Impaired Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2050.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Mild Impaired Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2050.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Healthy Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2050.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2050</intervention_name>
    <description>ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.</description>
    <arm_group_label>Cohort 1: Severe Impaired Renal Function</arm_group_label>
    <arm_group_label>Cohort 2: Moderate Impaired Renal Function</arm_group_label>
    <arm_group_label>Cohort 3: Mild Impaired Renal Function</arm_group_label>
    <arm_group_label>Cohort 4: Healthy Control</arm_group_label>
    <other_name>ACH-0145228 (formerly)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body weight must be at least 50.0 kilograms (kg) and body mass index (BMI) within the&#xD;
             range of 18.0 - 40.0 kg/meter squared (m^2) (inclusive) at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          2. Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          3. Must agree to receive prophylactic antibiotics to mitigate the potential risk of&#xD;
             meningococcal infection.&#xD;
&#xD;
             Participants with Impaired Renal Function&#xD;
&#xD;
          4. Aside from impaired renal function, sufficiently healthy for study participation based&#xD;
             upon medical history, physical examination, neurological examination, laboratory&#xD;
             tests, vital signs, and electrocardiograms (ECGs).&#xD;
&#xD;
          5. A clinical diagnosis of impaired stable renal function.&#xD;
&#xD;
          6. No clinically significant change in renal status at least 1 month prior to first dose&#xD;
             of study intervention and is not currently or has not previously been on hemodialysis&#xD;
             or did not have any history of peritoneal dialysis.&#xD;
&#xD;
          7. Stable creatinine clearance.&#xD;
&#xD;
          8. Must be on a stable medication regimen. Concomitant medications must be approved by&#xD;
             Alexion unless presented in the list of common concurrent medications for participants&#xD;
             with impaired renal function.&#xD;
&#xD;
             Matched Healthy Control Participants with Normal Renal Function&#xD;
&#xD;
          9. Must match the sex and the race (similar ratio of white and non-white) of participants&#xD;
             with impaired renal function, and at screening, age must be within ± 10 years and BMI&#xD;
             must be within ± 20% of the matching participants with impaired renal function&#xD;
&#xD;
         10. Healthy as determined by medical evaluation, including medical history, physical&#xD;
             examination, neurological examination, laboratory tests, vital signs, and ECGs, and&#xD;
             who possess a baseline eGFR ≥ 90 mL/min/1.73 m^2, based on MDRD equation at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of seizures, head injury, head trauma, or any other brain&#xD;
             disorder.&#xD;
&#xD;
          2. History of procedures that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          3. History of meningococcal infection or a first-degree relative with a history of&#xD;
             meningococcal infection.&#xD;
&#xD;
          4. Body temperature ≥38.0°Celcius at screening or check-in or history of febrile illness&#xD;
             or other evidence of infection, systemic or otherwise, within 14 days prior to the&#xD;
             first dose of study intervention.&#xD;
&#xD;
          5. Complement classical pathway hemolysis activity results outside the reference ranges&#xD;
             at screening, unless approved by Alexion.&#xD;
&#xD;
          6. Significant blood loss or donation of blood within 3 months prior to the first dose of&#xD;
             study intervention, donation of plasma within 30 days prior to the first dose of study&#xD;
             intervention, receipt of blood products within 6 months prior to first dose of study&#xD;
             intervention, or receipt of a vaccine within 30 days prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          7. Current enrollment or past participation within the last 30 days (or 5 half-lives,&#xD;
             whichever is longer) prior to the first dose of study intervention in the current&#xD;
             clinical study or any other clinical study involving an investigational study&#xD;
             intervention or any other type of medical research.&#xD;
&#xD;
          8. History or presence of drug or alcohol abuse within 6 months prior to the first dose&#xD;
             of study intervention, current tobacco user, or positive results for alcohol and/or&#xD;
             drug screen at screening or check-in.&#xD;
&#xD;
          9. Pregnant or lactating.&#xD;
&#xD;
         10. Does not produce sufficient urine output to permit urine sampling at screening and/or&#xD;
             check-in or has a history of urinary incontinence prior to check-in.&#xD;
&#xD;
         11. History of kidney transplant or actively on a transplant waiting list prior to&#xD;
             check-in.&#xD;
&#xD;
         12. Any acute or chronic non-renal condition prior to check-in that would limit the&#xD;
             participant's ability to complete or participate in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>ALXN2050</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

